Horizons in Cancer Research. Volume 73

Hiroto S. Watanabe (Editor)

Series: Horizons in Cancer Research
BISAC: MED062000

Clear

$250.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

In Horizons in Cancer Research. Volume 73, after the identification of some small subgroups with a strong biological-molecular identity, the current evidence regarding the prognostic factors of patients with non-eradicable metastatic disease are examined. The goal is to discuss disease subgroups, which may sometimes provide conditions for decisions that are less compliant with current clinical practice and help define new stratification criteria for patients enrolled in prospective studies.

Following this, the authors summarize the current knowledge on breast cancer with an introduction on the traditional markers used in the diagnosis of this disease, followed by an account of the emerging markers.

Next, the underlying mechanisms of DNA replication, damage and repair are discussed. Further, RAD51 is proposed as a potential means of managing chemoresistant cancers. Certain drugs and strategies can sensitize chemotherapy via impacting on RAD51, which can be developed as chemotherapy modulators.

The authors also discuss multiple myeloma, an incurable malignant tumor of plasma cells of the bone marrow, which is the most common primary neoplasm arising in bone. It causes approximately 1% of cancer-related deaths and is the 2nd most common hematological malignancy in the western world.

Later, this collection discusses the prevalence and types of infectious complications that patients with multiple myeloma face, as well as present and emerging therapeutic approaches.

The concluding study indicates proteins that have a promising future as new anticancer drugs, in conjunction with the in vitro and/or in vivo effects of these bioactive proteins derived from plants.
(Imprint: Nova Medicine and Health)

Preface

Chapter 1. Current Views on Prognostic Factors of Patients with Metastatic Pancreatic Adenocarcinoma
(Giuseppe A Colloca, MD, Antonella Venturino, MD, and Domenico Guarneri, MD, Oncologia Medica Imperiese, Imperia, Italy)

Chapter 2. Novel Molecular Markers of Breast Cancer
(K. Vaidyanathan, Professor and Head, Department of Molecular Biology, Amrita Institute of Medical Science and Research Center, Kochi, Kerala, India)

Chapter 3. RAD51 Is Involved in Cisplatin Resistance in Ovarian Cancer
(Guanhua Qian and Tinghe Yu, Key Medical Laboratory of Obstetrics and Gynecology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China)

Chapter 4. Multiple Myeloma: An Overview, Clinical Updates and Advances in Management
(Haroon Majeed, Consultant Trauma and Orthopaedic Surgeon, Manchester University Foundation NHS Trust, Manchester, England)

Chapter 5. Infectious Complications in Multiple Myeloma
(Nina Kumar and Lokesh Shahani, MD, Rice University, Houston, TX, US, and others)

Chapter 6. Plant-Derived Lectins: A Review of Their Status as Alternatives to Anticancer Chemotherapy
(Leydianne L. S. Patriota, Jéssica S. Brito, Dalila B. M. Ramosa, Thamara F. Procópio, Patrícia M.G. Paiva, Emmanuel V. Pontual, Cristiane M.L. Melo and Thiago H. Napoleão, Departamento de Bioquímica, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil, and others)

Index

You have not viewed any product yet.